Review Article
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies
Table 4
Randomized trials studying dose escalation in high-risk patients.
| | Trial | Study cohort | Median
follow-up | Trial arms | Outcomes |
| MDACC
Kuban et al. [24] | 301 patients
20% low-risk
46% int.-risk
34% high-risk | 8.7 years | 70 Gy versus 78 Gy
4-field box or 3DRT techniques
No ADT used | 8-year BRFS 55% versus 78% ()
8-year OS 78% versus 79% (NS)
High-risk cohort: 8-year BRFS 26% versus 63% ()
1% versus 7% grade 3 late toxicity () |
| | Dutch [25, 26] | 664 patients T1b-4
18% low-risk
27% int.-risk
55% high-risk | 5.8 years | 68 Gy versus 78 Gy
3DRT technique
ADT used | 7-year BRFS 45% versus 56% ()
OS not significantly different
Late grade 3+ GI (4% versus 5%) and GU toxicity (12% versus 13%) equivalent in both arms |
| UK
MRCRT01 [27, 28] | 843 patients
19% low-risk
37% int.-risk
43% high-risk | 10 years | 64 Gy versus 74 Gy
3DRT technique
ADT used | 10-year BRFS 43% versus 55% ()
OS not significantly different
6% versus 10% grade 3 late toxicity |
|
|
BRFS: biochemical relapse-free survival, NS: nonsignificant, and OS: overall survival.
|
